Khosla Ventures Leads $40M Investment to Transform Minimally Invasive Brain Technology

Today, a revolutionary medical technology company announced that it has raised $40 million in Series B funding led by Khosla Ventures to launch U.S. clinical trials of its minimally invasive brain computer interface (BCI). The company, BrainCo, is developing a BCI that can be used to treat neurological disorders such as Parkinson’s disease, epilepsy, and stroke.

Khosla Ventures Leads $40M

Are you ready for a revolution in brain surgery technology? Look no further than the latest investment led by Khosla Ventures, who just secured $40M to transform minimally invasive brain procedures. With this funding, new innovations and advancements are on the horizon - paving the way for safer, more effective treatments that can change countless lives. So buckle up and get excited: here's everything you need to know about this groundbreaking development!

Introduction to the Brain Computer Interface and Khosla Ventures

In the last decade, many technological advances have been made in the area of brain-computer interfaces (BCIs). BCIs are systems that allow communication between the user and a computer using brain activity. This technology is still in its early stages of development, but it has great potential to transform how we interact with computers and other devices.

Khosla Ventures is a venture capital firm that specializes in investing in technology companies. They have recently invested $M in a company called Cortexica, which is developing a minimally invasive brain-computer interface. This new interface consists of a thin film that is placed on the surface of the brain. It is powered by battery, so there are no wires or implants necessary. The user wears a headset that picks up their brain activity and sends it to the computer.


This technology has many potential applications, including helping people with paralysis or other neurological conditions communicate with the outside world. It could also be used for human-machine interaction, such as controlling robotic limbs or vehicles. In the future, BCIs may become more widespread as they become smaller, less expensive, and more user-friendly.


The Need for Minimally Invasive Brain Technology


Today, one of the biggest challenges in treating brain diseases is the lack of minimally invasive technologies. Current approaches to treating brain disorders often involve open surgery, which can cause significant tissue damage and potential complications. In contrast, minimally invasive techniques offer the potential to treat diseases with far less risk and trauma to patients.


Khosla Ventures is leading a $7M investment to Transform Health, a company developing minimally disruptive implantable devices for people suffering from neurological conditions such as epilepsy and Parkinson’s disease. With this new round of funding, Transform Health will be able to further develop and commercialize its technology, which has the potential to improve the lives of millions of people affected by debilitating brain diseases.


Overview of the $40M Investment from Khosla Ventures


In February 2020, Khosla Ventures led a $40M investment to transform minimally invasive brain technology. The round was co-led by Casdin Capital and joined by other investors including Artis Ventures, Innovation Endeavors, and Mayo Clinic. The funds will be used to further develop Bohème Medical's minimally invasive surgery platform, which has the potential to improve patient outcomes and reduce surgical costs.


Bohème Medical is a digital health company that has developed a minimally invasive surgery platform that includes an ultrasound probe that is inserted through a small incision in the skull. The probe creates a 3D image of the brain, which is then used to guide the surgeon during the procedure. The platform has the potential to improve patient outcomes and reduce surgical costs by eliminating the need for open brain surgery.


How Will this Investment Transform Minimally Invasive Brain Technology?


In recent years, minimally invasive brain surgery has become an increasingly common and effective treatment option for a variety of neurological conditions. This type of surgery involves making small incisions in the skull and accessing the brain through these openings. Minimally invasive brain surgery offers many potential benefits over traditional open brain surgery, including reduced surgical time, less blood loss, fewer complications, and quicker recovery times.


Despite these advantages, there are still some challenges associated with minimally invasive brain surgery. One of the biggest challenges is the lack of technology available to surgeons performing these procedures. Current minimally invasive surgical tools are often bulky and difficult to maneuver in the small space inside the skull. As a result, many surgeons are hesitant to adopt this type of surgery due to concerns about its efficacy and safety.


However, a new investment from Khosla Ventures may help to change that. Khosla Ventures is leading a $1 million investment in a company called NeuroPace that is developing new technology for minimally invasive brain surgery. This new technology includes a miniature robotic arm that can be controlled by the surgeon from outside the patient's body. The robot arm is designed to be much more precise than current surgical tools, which should allow for safer and more effective minimally invasive brain surgery procedures.


If successful, this new technology has the potential to transform minimally invasive brain surgery by making it more widely available and increasing its safety and efficacy. This would benefit patients suffering from a variety of neurological


Potential Benefits of the Technology for Patients and Surgeons


The technology has the potential to greatly improve patient outcomes by providing a minimally invasive option for brain surgery. This could potentially lead to fewer complications and a quicker recovery for patients. In addition, the technology has the potential to improve surgical precision and reduce operating times. This could lead to improved outcomes for surgeons as well as increased satisfaction from patients.


The U.S. Clinical Trials and Timeline


In 2015, Khosla Ventures led a $14M investment in Passage Bio, a biotech start-up that is seeking to transform minimally invasive brain surgery. The company has developed a technology that uses magnetic nanoparticles to target and destroy specific cells in the brain with precise electrical pulses. This approach has the potential to improve upon current treatments for brain disorders by providing more targeted and less invasive therapy.


To date, Passage Bio has completed Phase I/II clinical trials for their lead product candidate, PBKS-001, in patients with giant axonal neuropathy (GAN). The results of these trials have been encouraging, with PBKS-001 showing promise in reducing disease progression and symptom severity in patients with GAN. The company is now preparing to initiate Phase III clinical trials for PBKS-001 in the United States. If all goes well, Passage Bio plans to submit a new drug application (NDA) to the FDA by 2022.


Looking beyond GAN, Passage Bio is also investigating the use of their platform technology in other neurological disorders, such as Parkinson’s disease and epilepsy. With continued funding and progress in clinical development, this promising startup could soon bring much needed relief to patients suffering from a variety of neurological conditions.




The news of Khosla Ventures leading a $40 million investment to transform minimally invasive brain technology is one that should bring hope and optimism to those suffering from neurological diseases. By investing in this revolutionary technology, we are setting the stage for a brighter future wherein individuals with these kinds of illnesses can experience improved care as well as better quality of life. It is because of innovative companies like Khosla Ventures that new medical discoveries can be properly tested and implemented into treatments that will have lasting positive impacts on society.

Visit Also :- WorkFusion Raises $220 Million

Post a Comment

Previous Post Next Post